Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Goepfert

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Journal of Virology|July 30, 2005
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesMing Li, Feng Gao, John R Mascola, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 2, 2002
Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022AKalpana Gupta, Michael Hudgens, Lawrence Corey, et al.
The Journal of Experimental Medicine|August 24, 2016
Balance between transmitted HLA preadapted and nonassociated polymorphisms is a major determinant of HIV-1 disease progressionDaniela C Mónaco, Dario A Dilernia, Andrew Fiore-Gartland, et al.
Journal of Virology|May 18, 2007
Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infectionHayley Crawford, Julia G Prado, Alasdair Leslie, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2005
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infectionMichael R Betts, Barbara Exley, David A Price, et al.
Journal of Global Health|June 23, 2023
Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global regionShelly Karuna, Jorge A Gallardo-Cartagena, Deborah Theodore, et al.
Vaccine|January 11, 2011
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjectsMichael C Keefer, Sharon E Frey, Marnie Elizaga, et al.
Frontiers in Immunology|November 12, 2021
Cross-Reactivity to Mutated Viral Immune Targets Can Influence CD8<sup>+</sup> T Cell Functionality: An Alternative Viral Adaptation StrategyJennifer Currenti, Becker M P Law, Kai Qin, et al.
Plos Pathogens|December 5, 2012
Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesisJessica L Prince, Daniel T Claiborne, Jonathan M Carlson, et al.
The Lancet. HIV|October 3, 2020
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyLindsey R Baden, Daniel J Stieh, Michal Sarnecki, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Journal of Virology|July 30, 2005
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesMing Li, Feng Gao, John R Mascola, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 2, 2002
Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022AKalpana Gupta, Michael Hudgens, Lawrence Corey, et al.
The Journal of Experimental Medicine|August 24, 2016
Balance between transmitted HLA preadapted and nonassociated polymorphisms is a major determinant of HIV-1 disease progressionDaniela C Mónaco, Dario A Dilernia, Andrew Fiore-Gartland, et al.
Journal of Virology|May 18, 2007
Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infectionHayley Crawford, Julia G Prado, Alasdair Leslie, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2005
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infectionMichael R Betts, Barbara Exley, David A Price, et al.
Journal of Global Health|June 23, 2023
Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global regionShelly Karuna, Jorge A Gallardo-Cartagena, Deborah Theodore, et al.
Vaccine|January 11, 2011
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjectsMichael C Keefer, Sharon E Frey, Marnie Elizaga, et al.
Frontiers in Immunology|November 12, 2021
Cross-Reactivity to Mutated Viral Immune Targets Can Influence CD8<sup>+</sup> T Cell Functionality: An Alternative Viral Adaptation StrategyJennifer Currenti, Becker M P Law, Kai Qin, et al.
Plos Pathogens|December 5, 2012
Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesisJessica L Prince, Daniel T Claiborne, Jonathan M Carlson, et al.
The Lancet. HIV|October 3, 2020
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyLindsey R Baden, Daniel J Stieh, Michal Sarnecki, et al.
Pageof 6